Analysts expect Inovio Pharmaceuticals to post a Q2 2026 EPS loss of $0.24 following its earnings release next Tuesday.
Inovio Pharmaceuticals (INO) will release its Q2 2026 earnings results on August 11 after the market closes. The consensus estimate projects a loss of $0.24 per share for the quarter.
Over the past year, INO has beaten EPS estimates 50% of the time, while its revenue performance has also been mixed. The company has faced challenges in meeting analyst expectations consistently.
No immediate market reaction details are available ahead of the earnings release.